Outcomes After Aspirin Discontinuation Among Baseline Users in Contemporary Primary Prevention Aspirin Trials: A Meta-Analysis

HomeCirculationVol. 149, No. 9Outcomes After Aspirin Discontinuation Among Baseline Users in Contemporary Primary Prevention Aspirin Trials: A Meta-Analysis No AccessResearch ArticleRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessResearch ArticleRequest AccessFull TextOutcomes After Aspirin Discontinuation Among Baseline Users in Contemporary Primary Prevention Aspirin Trials: A Meta-Analysis Ruth Campbell, Mark R. Nelson, John J. McNeill and John W. McEvoy Ruth CampbellRuth Campbell National Institute for Prevention and Cardiovascular Health and School of Medicine, University of Galway, Ireland (R.C., J.W.M.E.). , Mark R. NelsonMark R. Nelson https://orcid.org/0000-0001-9941-7161 Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia (M.R.N.). Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (M.R.N., J.J.M.N.). , John J. McNeillJohn J. McNeill https://orcid.org/0000-0002-1049-5129 Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (M.R.N., J.J.M.N.). and John W. McEvoyJohn W. McEvoy Correspondence to: John W. McEvoy, MBBCh, BAO, MHS, PhD, National Institute for Prevention and Cardiovascular Health and School of Medicine, University of Galway, Croi House, Moyola Ln, Newcastle, Galway, H91FF68, Ireland. Email E-mail Address: [email protected] https://orcid.org/0000-0001-6530-5479 National Institute for Prevention and Cardiovascular Health and School of Medicine, University of Galway, Ireland (R.C., J.W.M.E.). Originally published26 Feb 2024Circulation. 2024;149:722–724FootnotesFor Sources of Funding and Disclosures, see page 724.Circulation is available at www.ahajournals.org/journal/circCorrespondence to: John W. McEvoy, MBBCh, BAO, MHS, PhD, National Institute for Prevention and Cardiovascular Health and School of Medicine, University of Galway, Croi House, Moyola Ln, Newcastle, Galway, H91FF68, Ireland. Email Johnwilliam.mcevoy@universityofgalway.ieREFERENCES1. McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, Reid CM, Lockery JE, Kirpach B, Storey E, et al; ASPREE Investigator Group. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly.N Engl J Med. 2018; 379:1509–1518. doi: 10.1056/NEJMoa1805819CrossrefMedlineGoogle Scholar2. Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, Howard G, Pearson TA, Rothwell PM, Ruilope LM, et al; ARRIVE Executive Committee. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.Lancet. 2018; 392:1036–1046. doi: 10.1016/S0140-6736(18)31924-XCrossrefMedlineGoogle Scholar3. Group ASC. Effects of aspirin for primary prevention in persons with diabetes mellitus.N Engl J Med. 2018; 379:1529–1539. doi: 10.1056/NEJMoa1804988CrossrefMedlineGoogle Scholar4. Sundstrom J, Hedberg J, Thuresson M, Aarskog P, Johannesen KM, Oldgren J. Low-dose aspirin discontinuation and risk of cardiovascular events: a Swedish nationwide, population-based cohort study.Circulation. 2017; 136:1183–1192. doi: 10.1161/CIRCULATIONAHA.117.028321LinkGoogle Scholar5. Nelson MR, Polekhina G, Woods RL, Reid CM, Tonkin AM, Wolfe R, Murray AM, Kirpach B, Ernst ME, Lockery JE, et al. Safety of ceasing aspirin used without a clinical indication after age 70 years: a subgroup analysis of the ASPREE randomized trial.Ann Intern Med. 2022; 175:761–764. doi: 10.7326/M21-3823CrossrefMedlineGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetails February 27, 2024Vol 149, Issue 9 Advertisement Article InformationMetrics © 2024 American Heart Association, Inc.PMID: 38408145 Originally publishedFebruary 26, 2024 Keywordsaspirincardiovascular diseasesprimary preventionPDF download Advertisement SubjectsCardiovascular DiseasePrimary Prevention